IMMUNE-MEDIATED HYPOPITUITARISM

This adverse event was reported 33 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED HYPOPITUITARISM:

# Drug Count
0 NIVOLUMAB 16
1 IPILIMUMAB 15
2 PEMBROLIZUMAB 10
3 CARBOPLATIN 3
4 PACLITAXEL 2
5 PACLITAXEL (AIBUMIN-BOUND) 2
6 PEMETREXED 2
7 PEMETREXED DISODIUM 2
8 CISPLATIN 1
9 CYCLOPHOSPHAMIDE 1
See all common drugs associated with IMMUNE-MEDIATED HYPOPITUITARISM

IMMUNE-MEDIATED HYPOPITUITARISM is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 IPILIMUMAB 15 0.0003
1 TREMELIMUMAB 1 0.0002
2 NIVOLUMAB 16 0.0002
3 ENFORTUMAB VEDOTIN 1 0.0001
4 VIBEGRON 1 0.0001
5 PEMBROLIZUMAB 10 0.0001
6 PEMETREXED DISODIUM 2 0.0001
7 DURVALUMAB 1 0.0000
8 LENVATINIB 1 0.0000
9 OLMESARTAN MEDOXOMIL 1 0.0000
See all drugs enriched for association with IMMUNE-MEDIATED HYPOPITUITARISM